Jennifer Murff, NP
Gerontology · Pleasant View, TNNPI 1295128957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2023 at $849 and has fallen 78.2% since, to $185 in 2024.
Across 145 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$538
- AstraZeneca$354
- Novo Nordisk$325
- Astellas Pharma US Inc$226
- Lilly USA, LLC$183
- Sanofi-aventis U.S. LLC$74
- plus $521 from 15 others
What the payments were for
- Food & beverage$2,14296%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $538 |
| AstraZeneca | 25 | $354 |
| Novo Nordisk | 23 | $325 |
| Astellas Pharma US Inc | 7 | $226 |
| Lilly USA, LLC | 11 | $183 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| GSK | 4 | $53 |
| Abbott | 2 | $50 |
| Bayer | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Novartis | 2 | $36 |
| Exact Sciences | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| Amgen | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Pfizer | 1 | $19 |
| Merck | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
How this compares
$2,222 in reported general payments places this provider in the 85th percentile of 194 gerontology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 92 | $76,073 |
| OzempicSemaglutide | 33 | $48,643 |
| MounjaroTirzepatide | 33 | $37,441 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,111 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $25,378 |
| EliquisApixaban | 30 | $23,876 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $23,097 |
| XareltoRivaroxaban | 38 | $22,194 |
| MyrbetriqMirabegron | 39 | $20,867 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,619 |
| LinzessLinaclotide | 11 | $8,228 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $7,870 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $7,448 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,987 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $3,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $354 | $86,692105 claims |
| Novo NordiskOzempic | $325 | $48,64333 claims |
| Lilly USA, LLCMounjaro | $183 | $37,44133 claims |
| GSKTrelegy Ellipta | $53 | $32,11145 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $74 | $25,37830 claims |
| PfizerEliquis | $19 | $23,87630 claims |
| Johnson & JohnsonXarelto | $30 | $22,19438 claims |
| Astellas Pharma US IncMyrbetriq | $226 | $20,86739 claims |
| AbbVieLinzess, Synthroid | $538 | $9,25335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 194 gerontology providers in Tennessee.
Other gerontology in Pleasant View
- Sarah VannPleasant View$2K
- Lauren WellsPleasant View$1K
- David HughesKnoxville$476K
- Melissa RossGermantown$15K
- Erann BulmanKnoxville$13K
- Leah BalchGreeneville$9K
- Xiaoxiao ZhangNashville$8K
- Ashley WoodKnoxville$6K
- Erica LudtkeNashville$6K
- Sara ErgerCookeville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.